AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

156.2 USD

Average target price

174.4 USD

Spread / Average Target

+11.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+16.13%	242B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+43.59%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ROCHE HOLDING AG	+2.17%	224B
NOVARTIS AG	+12.97%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 02:48:02 01/07/2024 pm IST			5-day change	1st Jan Change
12,298 ^GBX	-0.47%		-1.35%	+16.13%

10:19am	AstraZeneca applies to the EMA for a Covid antibody	CF
09:54am	AstraZeneca: CHMP recommends Imfinzi and Lynparza	CF

AstraZeneca applies to the EMA for a Covid antibody	01:49pm	CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza	01:24pm	CF
Stocks called higher ahead of Thursday's election	12:12pm	AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application	12:10pm	MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU	12:10pm	MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment	11:45am	RE
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
European Equities Close Lower in Wednesday Trading	26/06	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	26/06	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	26/06	MT
AstraZeneca: Tagrisso approved in China for NSCLC	26/06	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	26/06	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	26/06	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	26/06	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	25/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	25/06
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	25/06	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	25/06	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	25/06	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	25/06	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	25/06	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	25/06	RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	25/06	ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL	25/06	CF